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Background.There is not yet an agreed adjuvant treatment formelanoma patients with American Joint Committee on Cancer stages
III B and C.We report administration of an autologous melanoma vaccine to prevent disease recurrence. Patients andMethods. 126
patients received eight doses of irradiated autologous melanoma cells conjugated to dinitrophenyl and mixed with BCG. Delayed
type hypersensitivity (DTH) response to unmodified melanoma cells was determined on the vaccine days 5 and 8. Gene expression
analysis was performed on 35 tumors from patients with good or poor survival. Results. Median overall survival was 88 months
with a 5-year survival of 54%. Patients attaining a strong DTH response had a significantly better (𝑝 = 0.0001) 5-year overall
survival of 75% compared with 44% in patients without a strong response. Gene expression array linked a 50-gene signature to
prognosis, including a cluster of four cancer testis antigens: CTAG2 (NY-ESO-2), MAGEA1, SSX1, and SSX4. Thirty-five patients,
who received an autologous vaccine, followed by ipilimumab for progressive disease, had a significantly improved 3-year survival
of 46% compared with 19% in nonvaccinated patients treated with ipilimumab alone (𝑝 = 0.007). Conclusion. Improved survival
in patients attaining a strong DTH and increased response rate with subsequent ipilimumab suggests that the autologous vaccine
confers protective immunity.
In loving memory of Olga Drize, Ph.D.
1. Introduction
The treatment of metastatic melanoma has been revolution-
ized in the last three years, with the FDA registration of
Yervoy, a monoclonal antibody blocking lymphocyte reg-
ulatory receptor cytotoxic T lymphocyte-associated antigen
4 (CTLA-4), and shortly afterward, the entry to the clinic
of Zelboraf, a small molecule inhibitor of mutated B-RAF.
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From being an incurable disease, stage IV melanoma has
become an illness in which prolonged and even complete
responses can be envisioned. However, while the prospects
have improved for stage IV disease, for patients with Ameri-
can Joint Committee on Cancer (AJCC) stage III disease no
new treatment options have been developed and validated
since the approval of interferon 𝛼 (IFN𝛼) almost two decades
ago [1–7]. A pegylated formulation did not offer improved
tolerability and treatment was discontinued due to toxicity.
Both the EORTC trials and the ECOG pooled analysis [8]
showed that AJCC stage III patients with macroscopic lymph
node involvement derived the smallest survival benefit, if any,
from IFN𝛼.
In this situation, melanoma vaccines could have been an
alternative to IFN𝛼, since they could induce a tumor-specific
immune response to inhibit micrometastases at a stage when
the suppressive effects of an advanced tumor are not yet an
obstacle [9]. In the few controlled clinical trials reported
to date, vaccinated patients did not experience a survival
benefit [10]. This fact, together with the paucity of objective
responses to active immunization in stage IV melanoma
patients using different vaccination strategies, rendered a
general impression of the futility of cancer vaccines [11, 12].
The resurgence of interest in cancer vaccination was
the result of several clinical trials demonstrating that a
component of active immunization could improve clinical
outcome of immunotherapy protocols. Examples include the
addition of a peptide vaccine to the administration of high
dose interleukin-2 (IL-2) [13] and the use of a GMCSF-
secreting tumor vaccine in combination with CTLA-4 block-
ade for metastatic prostate cancer [14]. These trials led to
the increasing understanding that cancer immunotherapy is
a multifaceted strategy and that a single treatment modality
would not suffice. Noting that individuals exhibit heterogene-
ity of tumor antigens [15], the use of autologous tumor as a
basis for vaccination can provide antigen authenticity. The
unique expression profile of normal and mutated proteins in
the patient’s tumor cells is presented in conjunctionwith their
own major histocompatibility complex (MHC) molecules,
and this combination is necessary to induce antigen-specific
reactive lymphocytes [16]. The coadministration of Bacillus
Calmette-Guérin (BCG), a widely used immunological adju-
vant, with the autologous vaccine, has previously been shown
to enhance response to autologous vaccination protocols [17,
18].
In this paper we report our experience with an autologous
melanoma vaccine as an adjuvant therapy for melanoma
patients in the advanced categories of AJCC stage III disease:
macroscopic lymph node involvement and resectable in-
transit metastases. We demonstrate that clinical immune
response (delayed type hypersensitivity, DTH) is linked to
improved survival. Furthermore, using this vaccination pro-
tocol,molecular analysis of themelanoma showed that cancer
testis antigens (CTAs), which are generally considered targets
of immune response, are predictive of survival. Interestingly,
patients who had previously received the melanoma cell
vaccine had improved overall survival when treated with
ipilimumab immunotherapy for metastatic disease.
2. Materials and Methods
2.1. Patients. This prospective phase II, single-institution,
single-arm study includedpatientswith operableAJCC stages
IIIB and Cmelanoma. Clinical staging was based on palpable
lymph nodes and/or satellites prior to surgery. Since we
did not have pathological data on ulceration of the primary
melanoma for all patients, AJCC stage IIIB was defined for
any T (tumor) with pathological N1b, N2b, and N2c. Stage
IIIC was defined as any T with pathological N3 [19].
2.2. Outcomes. The aim of the study was to document overall
and disease-free survival (primary outcome) and to correlate
skin reactivity to the autologous tumor of patients that were
treated with the autologous melanoma cell vaccine with
survival (secondary outcome).
2.3. Inclusion and Exclusion Criteria. To participate, patients
had to undergo complete removal of their metastatic disease
and have a normal CT scan within 30 days prior to vaccina-
tion. Additional inclusion criteria included an age of 18 years
or older, normal liver and renal function tests, baseline lactate
dehydrogenase (LDH) value below the laboratory upper limit
of normal, and ability to provide informed consent. Exclusion
criteria included primary ocular melanoma. Fertile patients
were requested to use adequate anticonceptive measures
throughout the study period.
Screening procedures included baseline blood analyses
(hematological, chemical) and computed tomography (CT)
and/ormagnetic resonance imaging (MRI) of the entire body,
including the brain, every 4 months in the first 2 years and
then every 6months for 10 years.The studywas not sponsored
and was conducted following approval by the institutional
ethics committee; written informed consent was obtained
from all patients. Seventy-five patients from this group were
included in an immune monitoring study reported earlier
[16].
2.4. Melanoma Cell Lines. For the preparation of the autol-
ogous vaccine, melanoma cell lines were established from
resected metastases. All patients gave their informed con-
sent to receive the vaccine. The melanoma cell lines were
established and cultured as described [18]. Briefly, cells
were extracted mechanically from fresh and sterile tumor
specimens, frozen, and stored in liquid nitrogen in a medium
containing 2.5% human albumin and 20% DMSO until
needed. To assure melanocytic progeny, the expressions of
S100, MART-1, and gp100 were determined by immunostain-
ing using polyclonal rabbit anti-S100, monoclonal A-103, and
HMB-45 Abs, respectively (Dako). Positive staining of more
than 50% of cells with at least one of these antibodies was
required. MHC class I-related chain A (MICA) expression
was determined by flow cytometry of melanoma cell lines
using anti-human MICA-APC (Allophycocyanin), R&D sys-
tems, Minneapolis, MN, USA.
Cell lines were routinely tested for mycoplasma contam-
ination by EZ-PCR (Biological Laboratories, Beth Haemek,
Israel), according to the manufacturer’s instructions. Tumor
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cultures that were found contaminated were incubated in the
presence of 10mg/mL Ciproxin 200 (Bayer) for two weeks,
with change of medium every three days. The cells were
retested after treatment and were used only after being found
mycoplasma-free.
2.5. Vaccine Preparation and Vaccination Procedure.
Melanoma cell lines were expanded to the required number
necessary for preparation of at least 8 vaccine doses of
10–25 × 106 cells each and cryopreserved at −70∘C. On the
day of treatment, one dose of cells was thawed, washed,
and irradiated to a dose of 230Gy. At this stage, cells were
still viable. Conjugation of melanoma cells with DNP was
performed as described [20], leading to death of the cells
(as determined by trypan blue exclusion). BCG (Statens
Serum Institut, Denmark) was added to the vaccine prior to
injection, diluted to 1 : 50 for the first three vaccine doses and
up to 1 : 500 for the following doses, to avoid overreactivity at
the injection site. BCG was reported to trigger dendritic cell
maturation and to aid in diverting the CD4 T cell response
towards a Th1 phenotype [21]. The vaccination procedure
was carried out as described [18]. Briefly, patients were
sensitized to DNP, to enhance the response to the vaccine,
by applying 0.1mL of 2% DNP dissolved in acetone-corn
oil (Sigma) topically to the inner aspect of the arm ten days
prior to injection of the first vaccine. Cyclophosphamide,
300mg/m2 per dose, was given 4 days preceding the first and
second vaccines. This practice was based on the observation
that cyclophosphamide prior to vaccination can reduce the
proportion of T regulatory cells and enhance tumor-specific
immune response [22–25]. Generally, vaccines were injected
in 3 adjacent sites on the upper arm or thigh, avoiding limbs
with dissected lymphatic basins. Each patient received eight
vaccine doses, at three-week intervals.
Patients were evaluated periodically every 3 months and
had a total body CT scan performed every 6 months, or as
required according to their symptoms.
2.6. DTH Reaction. Evaluation of DTH to autologous
melanoma cells was performed on the vaccine days 5 and
8, by intradermal injection of 1–3 × 106 irradiated (170Gy)
autologousmelanoma cells.TheDTHresponsewasmeasured
48 h after injection. Erythema diameter of 5mm and less
was arbitrarily defined as negative; 5–10mmweak; 10–15mm
positive; and ≥15mm strong positive DTH.
2.7. Gene Expression andConnectivityMapAnalysis (C-MAP).
Thirty-five melanoma cell lines that were retrieved from 35
vaccinated patients were selected for gene expression analysis
based on retrospective survival data of the donors. Gene
expression profiling was performed using an assay based on
a collection of cellular genomic signatures that produced a
pattern-matching tool and formulation-based deduction of
a wider expression profile. One thousand transcripts were
identified, from which the remainder of the transcriptome
could be computationally inferred. These 1,000 “landmark”
transcripts were measured on Luminex beads, as part of
the Connectivity Map (C-MAP) project (unpublished, R.
Narayan, Broad Institute of Harvard University and MIT,
Cambridge,MA). Cultures underwent amedian of 4 passages
(range 2–13) and mRNA was extracted from melanoma
cell microcultures harvested at 90% to 100% confluence,
produced in a synchronous way, under identical conditions
of growth, in four replicates. Initial analysis was conducted
with a bioconductor- (R-) based test (SSAT), which applies
a Cox-regression analysis followed by a second test based on
rank statistics. The analysis determines the best cut-off value
that separates patients into those with favorable versus worse
survival time.
2.8. Quantitative Real Time PCR (qRT-PCR). Applied
Biosystems premade and custom primer probes designed
with NCBI Primer–Blast Tool were used (http://www.ncbi
.nlm.nih.gov/tools/primer-blast/). RNA was normalized to
GAPDH-RNA content using ABI 7500 SDS software, v1.2.2
(Applied Biosystems Inc., Foster City, CA). Positive and
negative controls, as well as samples with no DNA, were
included in every qRT-PCR experiment. PCR reactions were
performed using ABI qRT-PCR thermocycler (7500 Real
Time PCR System, Applied Biosystems Inc., Foster City,
CA). The qRT-PCR program was run for 45 cycles, following
an initial incubation at 95∘C, 10min. Each cycle consisted of
95∘C× 15 sec and 60∘C × 1min.
B-RAF genotype was determined using Cobas 4800
(Roche).
2.9. Patients Undergoing Ipilimumab Treatment. During
the autologous vaccine study period, ipilimumab (Yervoy,
BMS) was administered in our institution to patients with
metastatic melanoma in the framework of BMS studies
CA184-004, 024, and 025. Since its FDA approval as a
standard second-line treatment, ipilimumab was given after
a one- or two-dose course of DTIC. Patients from the autol-
ogous vaccine study which later developed nonresectable
metastatic disease were among a larger group recruited for
these protocols. Survival data is reported for all patients
getting ipilimumab during 2007–2014.
2.10. Statistical Method. The comparison of survival curves
between groups was carried out using the Kaplan-Meier
Survival analysis with the log rank test. All tests applied
were two-tailed, and a 𝑝 value of 5% or less was considered
statistically significant.
3. Results
3.1. Study Patients. Melanoma metastases were obtained
from 159 eligible patients. From 33 patients (20%) we could
not generate the number of cells required for the treatment.
A total of 126 patients (55% male; median age, 59 years)
with postoperative AJCC stages IIIB and C (45% stage IIIB;
55% stage IIIC) were enrolled. For patient characteristics
see Table 1. Twenty-four patients (19%) presented with
enlarged lymph nodes (LNs) at the time of diagnosis of the
primary melanoma; 11 (9%) had unknown primary lesion;
22 (17%) had metastases in transit. Nineteen patients (15%)
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Table 1: Patients characteristics.
Patients 126





Breslow Median 3.05mm (0.2–20)









Number of involved LNs, mean (range) 2.4 (0–17)
Adjuvant radiotherapy 56 (44%)
had noninvolved sentinel LN but developed macroscopic
disease later, in the same lymphatic basin. Forty-two patients
(33%) had not undergone a sentinel LN biopsy and developed
macroscopic LN involvement. The mean number of involved
lymphnodeswas 2.4, ranging from0 (satellites) to 17. Fifty-six
patients (44%) had undergone radiotherapy in addition to the
surgical procedure, which was added when more than three
nodes were involved or in cases of extracapsular invasion by
melanoma cells.
3.2. Vaccine Safety. No grade 3-4 adverse events (CTCAE
V4) were encountered among the 126 vaccinated patients.
In all patients, an erythematous nodule developed at the
vaccination site and resolved in the course of 3–6 months
leaving a depressed scar.
3.3. Patient Survival Correlates with Intensity of Evolving
DTH Response to Unmodified Melanoma Cells. The OS and
disease-free survival (DFS) of participating patients were
measured from the day of the first vaccine until the current
analysis was performed. A total of 126 patients were included,
with a median follow-up of 44.5 months (range 8–189
months). OS survival data was available for all 126 patients
and DFS data was available for 107 patients. OS and DFS
were analyzed for DTH < 15mm (weak/positive DTH) versus
DTH > 15mm (strong positive DTH). Overall, for the whole
cohort, the 5-year OS was 54% and DFS was 34%. There
was no difference between OS of stage IIIB and IIIC patients
(𝑝 = 0.182). Of 119 patients with recorded DTH response, 48
patients (40%) attained strong positiveDTH (DTH> 15mm),
whereas 71 (60%) had a weak DTH response (<15mm). The
patients with strong DTH response had a 5-year OS of 75%
and DFS of 47%. In contrast, patients with weak DTH had
a significantly lower 5-year OS of 44% (𝑝 < 0.0001) and
DFS of 26% (𝑝 = 0.27). Using the Kaplan-Meier analysis
and the log rank test, the single parameter that most strongly
correlated with OS and DFS in a univariate analysis was
the DTH response (Figure 1). In Table 3, OS and DFS are
compared between patients attaining DTH responses of 10
and 15mm and patients who did not develop such response.
For patients who attained strong positive DTH (>15mm), the
5-year overall survival hazard ratio (HR) was 0.24 (95% CI
0.1–0.53; 𝑝 < 0.001). The HR for 5-year disease recurrence
was 0.4 (95%CI 0.1–0.83, 𝑝 = 0.015 Pearson’s chi square test),
but in a longer follow-up, the protection from recurrence
decreased to a HR of 0.63 (95% CI 0.3–1.32; 𝑝 = 0.2). Age,
gender, and depth of invasion of the primary melanoma had
no impact on survival. In a survival analysis done for DTH
cut-off of 10mm, a similar trend was noted with a smaller
𝑝 value (0.003) for improved 5-year OS in patients attaining
a DTH response of >10mm (64%) versus 32% in patients
with DTH <10mm. DFS was similar in the two groups (𝑝 =
0.36).Thus, the acquisition of powerful skin reactivity against
nonmodified autologous melanoma cells, which reflects the
development of specific cell mediated immunity, correlates
favorably with survival, supporting previous results by us and
by others, for example, [16, 18, 26].
For 56 patients in whom more than 3 involved lymph
nodes were removed, radiation therapy was added to the
resected lymphatic basin. Even though the patients requiring
this added treatment belonged to a grave prognostic group,
radiotherapy may enhance the immune response of the
patients [27]. Indeed, the rate of strong DTH response in
patients receiving radiotherapy was 42%. Five-year OS of
these patients was 58% compared to 33% of those who
received radiotherapy and had a weak DTH response (𝑝 =
0.024).
3.4. Cancer Testis Antigen mRNA Expression in Melanoma
Cells Correlates with Improved OS. The C-MAP project was
based on a collection of cellular genomic signatures to drugs,
disease states, and cancer, in order to produce a pattern-
matching tool and a formulation-based deduction of a wider
expression profile. One thousand transcripts were identified
from which the remainder of the transcriptome could be
computationally inferred.These 1,000 “landmark” transcripts
were measured on Luminex beads (unpublished, R. Narayan,
Broad Institute of Harvard University and MIT, Cambridge,
MA).
Thirty-five tumor samples, representing distinct sub-
classes of poor and good responders, were selected for C-
MAP analysis: (1) eighteen poor responding patients with a
median OS of 19 months (range 8–34), all of whom failed
to develop strong skin reactivity to their autologous tumor,
and (2) seventeen good responding patients with median OS
of 105 months (range 46–194), 12 of whom also developed
strong skin reactivity (DTH data missing for one). Figure 2
shows the hierarchical clustering of 50 genes expressed on
patients’melanoma cells, which yield a significantly improved
or worsened HR for survival. Several genes of interest are
listed in Table 4. Cancer testis antigens CTAG2 (NY-ESO-
2), MAGEA1, SSX1, and SSX4 clustered together in the
hierarchical diagram (depicted in a circle in Figure 2). High



































































Figure 1: Kaplan-Meier survival curves of 126 melanoma patients with AJCC stages III B and C disease. (a) Survival data of all patients
undergoing autologous vaccination. (b) Correlation of survival with delayed type hypersensitivity (DTH) response to unmodified melanoma
attained following vaccination. OS: overall survival; DFS: disease free survival.
expression of each of these CTA genes was associated with
a reduced risk of death. As CTA genes are coexpressed, we
performed a principal component analysis (PCA) of the genes
to stratify the patients, using the “princomp” function in R.
We found the first principal component (PC1) to explain
more than 80% of the variance when expression values from
the 35 samples corresponding to all 51 probe sets from
CTA genes in the C-MAP array were used (Figure 3(a)). To
validate the predictive data extracted from C-MAP, we used
qPCR results obtained from 21 melanoma line samples for
MAGE-A1, SSX1, SSX4, and NY-ESO-1 (CTAG1B). Similar
to the in silico data, a PCA analysis based on these four
genes was able to explain 75% of the variance. In both
analyses, stratifying the patients into low/intermediate and
high expression based on PC1 values, we showworse outcome
for low CTA expressors (below quartile 1) compared to high











































































































































































































































































Figure 2: Hierarchical clustering gene expression of a 50-gene signature showing strongest association with prognosis in 35 stage III
melanoma patients. Cancer testis antigens CTAG2, MAGEA1, SSX1, and SSX4 are circled in a cluster. NED: no evidence of disease at time of
analysis; DOD: died of metastatic disease.
expressors (above quartile 4), 𝑝 = 0.02 (Figure 3). A similar
analysis performed using an unrelated melanoma cohort
(GSE19234 [28]), which never had an autologous vaccine, did
not reveal an association between CTA gene expression and
survival (not shown), suggesting that CTA gene expression
is not a prognostic factor by itself but becomes one in the
context of autologous vaccination.
MICA (MHC class I related chain A), another gene which
correlated with a reduced risk of death and for which there
is an antibody for flow cytometry, was used to validate
the expression data (Figure 4). Out of 11 samples analyzed,
10 yielded MICA protein expression (by flow cytometry)
concordant with the gene expression value. In 8 samples the
data was predictive of patient’s current status, whether alive,
no evidence of disease (NED), or died of disease (DOD).
3.5. B-RAF Status and Survival. B-RAF status was deter-
mined for 32 patients of the 35 that were analyzed for gene
expression. Eleven patients (33%) harbored the V600Emuta-
tion. The median survival for patients with V600E mutation
was 50 months compared with 45 months for the wild type
(WT) group (𝑝 = 0.9). Since most patients in the series
who had recurrent disease died before 2012, none of them
were treated with B-RAF inhibitors when they developed
metastases, and consequently differences in survival could
not be attributed to better treatment options. Four out of 11
patients with V600E mutations had strong DTH response
(36%), compared with seven out of 21 (33.3%) in the WT
group (𝑝 = 0.86).
3.6. Patients Who Received Melanoma Vaccine Had Improved
Survival following Ipilimumab Treatment for Advanced Dis-
ease. Thirty-five patients who received melanoma cell vac-
cine and developed nonresectable metastatic disease were
referred to ipilimumab treatment in BMS studiesCA 184-004,
024, and 025 and later as a standard second-line treatment.
These patients were compared with a nonselected concurrent
group of other 35 patients, who never received the vaccine
(Table 2). The majority, 62 patients (89%), received ipili-
mumab at a dose of 3mg/kg. Response Evaluation Criteria
in Solid Tumors (RECIST) were used to define response to
treatment. Complete response was achieved in six patients
(8.6%), partial response in 14 (20%), and stable disease in
7 (10%). Median OS of the group was 14 months (95% CI










































Figure 3: Overall survival curves stratifying the patients according to integrated cancer testis antigen genes expression. As CTA genes
are coexpressed, we performed a principal component analysis (PCA) of the genes to stratify the patients into low/intermediate and high
expression based on first principal component (PC1) values. (a) PC1 was determined in 35 melanoma lines based on all 51 probe sets from
CTA genes in the C-MAP array. (b) PC1 was determined in 21 melanoma lines based on qPCR data generated for CTAs MAGE-A1, SSX1,
SSX4, and NY-ESO-1 (CTAG1B).
5.7–22 months). Multivariate analysis revealed that the single
parameter that correlated with an improved OS time was
previous treatment with melanoma cell vaccine. In the group
of 35 vaccinated patients, median OS was 31 months with
a 3-year survival of 46%, compared with a median OS of
9 months and 3-year survival of only 19% in the nonvacci-
nated patients, (𝑝 = 0.007, Pearson’s chi square test). The
results from this retrospective cohort of patients suggest that
response rate and survival are improved when ipilimumab
treatment succeeds autologous melanoma vaccine.
4. Discussion
In this phase II study we administered a vaccine composed
of the autologous tumor given to melanoma patients as a
postoperative adjuvant for AJCC stage III disease following
resection of macro metastases. The study was single-armed,
as it was initiated prior to the registration of IFN𝛼 as standard
of care for the adjuvant treatment of melanoma stages IIB
and III. In an initial cohort, which included patients of
worse prognoses (stages IIIB, IIIC, and IV) we observed an
unexpected good survival rate with this vaccine [18]. In view
of the reduced toxicity of the vaccination regimen, we did not
offer patients a high dose interferon arm after its registration.
On the other hand, the inclusion of an observation arm was
ethically questionable. Thus, we opted to continue with the
protocol in its single-arm design, to record survival rates in
adjuvant stage IIIB and C patients. Eventually, these patients
were the less likely ones to derive benefit from adjuvant IFN𝛼
therapy, since treatment with the standard of care IFN𝛼-2b
or PEG-IFN did not yield any survival advantage for them
[29].The projected 5-year OS for these patients was estimated
at 40% and the DFS at 30%, as shown in the Kaplan-Meier
curves generated in ameta-analysis from EORTC trials 18952
and 18992 of patients with AJCC stage III-N2. In our group
of patients with the same stage disease, the 5-year OS reached
54%,with amedianOSof 88months and a 5-yearDFS of 34%;
these were achieved with nomajor adverse effects. In another
series, the Nordic study, the best median survival, 72 months,
was derived from intermediate-high doses of IFN𝛼-2b for one
year. These results, worse than those we observed with the
autologous vaccine, were generated in a group of patients in
which 35% had earlier stage disease (IIIA).
Notably, in our study population, patients with a strong
positive skin reaction to their unmodified melanoma had
much better prognosis, with a 5-year OS of 75% and DFS
of 44%. The link between immune parameters that attest
to the development of antitumor response and improved
survival has been previously observed [17, 30–36]. DTH is a
crude measurement, but an easy test to apply on all patients.



































































































































































































































































Figure 4: Flow cytometry analysis of MICA surface expression on melanoma cell lines. The number in the histogram is the Luminex 1000
expression value of MICA. Black histogram: background staining with isotype control Ab. Blue histogram: MICA staining with anti-MICA
specific Ab.
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Table 2: Clinical data and ipilimumab treatment results of 70
patients with AJCC stage IV melanoma who received or did not
receive melanoma vaccine.
Prior vaccination Yes No 𝑝∗
𝑛 % 𝑛 %
Patient number 35 50 35 50
M stage
M1A 8 23 3 9
0.3M1B 8 23 10 28
M1C 19 54 22 63
Dose
3mg/kg 30 86 32 91 0.45
10mg/kg 5 14 3 9
Reinduction 4 12 3 9
Treatment stopped for toxicity 5 14 2 6
Objective response
CR 3 9 3 9
0.03∗∗PR 10 29 4 11
S 6 17 1 3
P 16 46 27 77
Survival data
Median OS (months) 31 (3–47) 9 (2–50) 0.007
3-year survival rate 46% 19%
CR: complete response, PR: partial response, S: stable disease, and P:
progression.
∗Pearson chi square (two-sided) test.
∗∗𝑝 value for progression (P) versus any benefit (CR, PR, and S).
Several vaccine clinical trials included a DTH test as part of
their clinical evaluation and reported a positive correlation
between DTH response and longer survival [37, 38]. Biopsies
taken from skin injection sites revealed vaccine-induced
antigen-specific T cells [39, 40]. We previously demonstrated
effective antimelanoma CD4 T cell activity associated with
improved survival in a cohort included in the present study
[16]. Thus, a positive DTH reaction could be indicative of
the emergence of antimelanoma immunity, and the improved
survival of patients attaining strong DTH would attest to the
vaccine’s protective effects.
Since autologous tumor tissue is often not available for
vaccine preparation, defined antigens, consisting of short
or long peptides, are used as a substitution [41–43]. The
enthusiasm for the use of defined antigens decreased when
successful generation of antigen-specific T cells failed to
protect against tumor progression [11, 44]. Loss of MHC
and impaired peptide presentation by the melanoma were
among the reasons for vaccine failure, but another limitation
is that many tumor-progeny antigens are essentially self-
antigens that evokeweak responses [45].Unlikewildtype pro-
teins, mutations have the potential to generate neoantigens
which are better targets.The significance ofmutation-derived
neoantigens was illustrated when adoptively transferred
tumor-infiltrating lymphocytes that destroyed melanoma in
patients were surveyed and found to target mutated epitopes
[46]. Furthermore, recent data has clearly demonstrated that
these mutations are, in large part, the functional targets of
immune checkpoint blockade [47]. It may not take long until
“mutanome” libraries are generated for melanoma patients.
But until the hurdles of preparing a totally individualized
vaccine are overcome, the best source of mutated antigens, as
we have previously shown, is still the autologous tumor and,
ideally, those tumors that express both MHC class I and class
II [16].
Another important component of melanoma cell vac-
cines, as reflected by our data, are a class of antigens known
as cancer testis antigens. CTAs are products of several
multigene families, many of which map to chromosome X,
that have arisen through chromosomal duplications andwere
initially identified through immunologic assays [48]. When
associated with disease outcome, CTAs sometimes confer
worse prognosis [49], but when protective immune responses
are recorded, CTAs are dominant targets. For example,
rising antibody responses to CTA NY-ESO-1 (CTAG1B) were
recorded following shrinkage of melanoma in a patient with
abscopal tumor response [50], and among patients treated
with ipilimumab, seropositivity to NY-ESO-1 with associated
CD8 T cell response correlated with 77% clinical benefit [51].
Using a Luminex-based method to generate a gene
expression array and qPCR validation, we showed increased
expression of MAGEA1, CTAG1, CTAG2, SSX1, and SSX4
in patients with improved survival. We suggest that these
patients’ prolonged survival is attributed to the melanoma
immunogenicity potentiated by the CTAs and augmented by
the vaccination procedure.
Lastly, our data implies that patients who had been
immunized against the autologous tumor prior to receiving
ipilimumab survived longer than patients who did not receive
an autologous melanoma vaccine. The precise mechanism
of action of ipilimumab is not completely clear. CTLA-4
receptor blockade prevents inhibition of activated effector
lymphocytes and selective increase in the ratio between T
effectors and regulatory T cells within the tumor [52]. In
patients with preexisting immune response, the removal of
inhibitory signals boosts antitumor activity [51], leading to
the hypothesis that prior vaccinationmight induce in a subset
of patients a population of specific antitumor cytotoxic T cells
and a potent immune response following immune checkpoint
blockade. In this respect, it was encouraging to note that in a
cohort of vaccinated patients that had received ipilimumab,
the 3-year survival was 46%, compared with 19% for the
nonvaccinated patients (𝑝 = 0.007).
5. Conclusions
In this noncontrolled phase II study we have shown that
adjuvant treatment with autologousmelanoma vaccine yields
overall and disease-free survival rates that are not inferior
to those obtained with interferon alpha. In a subgroup of
patients who attained a strong positive skin response to
unmodified autologous tumor, survival rates were exception-
ally good, with a 5-year OS of 75%. Increased expression
of CTAs by the tumor correlated with improved survival.
Lastly, improved survival time following ipilimumab treat-
ment was observed for patients who had previously been
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Table 3: Patients survival data.
Number (%) 1 year (%) 2 years (%) 5 years (%) Median (mo, 95% CI) 𝑝 value
Overall survival
All∗ 126 93 77 54 88 (40–137)
DTH ≥ 15mm 48 (40) 100 93 75 Not reached
DTH < 15mm 71 (60) 89 70 44 45 (13–20) <0001
DTH ≥ 10mm 75 (63) 97 83 64 181 (75–287)
DTH < 10mm 44 (37) 87 66 32 41 (23–59) 0.003
Disease-free survival
All∗∗ 107 58 45 34 18 (5–31)
DTH ≥ 15mm 36 (36) 74 53 47 36 (0.00–87)
DTH < 15mm 65 (64) 55 42 26 15 (7–23) 0.27
Adjuvant radiotherapy
Overall survival
All 56 90 69 41 43 (27–59) 0.055
DTH ≥ 15mm 22 (42) 100 87 58 111
DTH < 15mm 31 (58) 84 56 33 31 (20–42) 0.024
∗DTH data was available for 119 of 126 patients.
∗∗DTH data was available for 101 of 107 patients with recorded disease-free survival.
Table 4: Selected genes expressed on melanoma cells which correlate with overall survival. The genes were depicted by Maxstat-package
utilizing a Cox-regression analysis followed by rank statistics to determine the best cut-off value which separates patients into favorable
versus unfavorable survival groups. ↑ = higher expression correlates with prolonged survival time; ↓ = higher expression correlates with
decreased survival time.
Gene ↑/↓ Full name Maxstat cutpoint Maxstat 𝑝 value
CoxPH hazard
ratio CoxPH 𝑝 value
MICA ↑ MHC class I-related chain A (NKG2D ligand) 7.8 0.018 0.5 0.015
CTAG2 ↑ Cancer testis antigen 2 (LAGE-1, NY-ESO-2) 5.9 0.014 0.58 0.015
SSX4 /// SSX4B ↑ Synovial sarcoma, X breakpoint 4 3.9 0.008 0.58 0.017
TGFA ↑ Transforming growth factor 𝛼 4.08 0.011 0.66 0.018
KIR3DX1 ↑ Killer cell Ig-like receptor 4 0.023 0.56 0.02
MAGEA1 ↑ Melanoma antigen family A, 1 5.52 0.042 0.69 0.028
SSX1 ↑ Synovial sarcoma, X breakpoint 1 3.28 0.035 0.63 0.043
SMAD1 ↓ SMAD family member 1 5.5 0.046 2.58 0.0002
HSPH1 ↓ Heat shock 105 kDa/110 kDa protein 1 10.7 0.008 1.9 0.007
vaccinated. Thus, we suggest that autologous melanoma
vaccine induces protective immunity and may offer leverage
for other immunotherapies.
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